aTyr Pharma (ATYR) Q2 2026 earnings

Published Aug 7, 2026

AI summary

GAAP EPS −$0.11 beat the −$0.13 consensus by $0.01, up from −$0.22 a year ago.
aTyr Pharma reported a net loss of $10.3 million for the second quarter of 2026.
The company is implementing a 60% workforce reduction to prioritize its efzofitimod program in ILD.
Enrollment is complete for the Phase 2 EFZO-CONNECT study, with topline results expected in early 2027.
The company ended the quarter with $58.9 million in cash, providing a runway into late 2028.

Revenue

Not reported in this release.

EPS · GAAP (street basis)

Reported · Diluted EPS (GAAP, street basis)

−$0.11

Consensus −$0.13

Beat by $0.01

GAAP EPS: −$0.11

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

No guidance in this release.

The company requires additional capital through future offerings or partnerships to fund its planned Phase 3 study.
The restructuring involves the departure of the current CFO and General Counsel.

Source: aTyr Pharma, Inc. press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.